[The events of the SARS-COV-19 pandemic have highlighted the need to focus on a number of tools and methods to improve the delivery of healthcare. Telemedicine can help in this innovation. The use of telemedicine during the Covid-19 pandemic was new in our country, but has long been used abroad. International experience, as well as that we gained during the covid pandemic, shows that the methodology is worth using in the domestic health care system in the future.  The primary aim of this paper is to introduce the concepts related to telehealth. A sub-objective is to briefly review international practice. With our study we want to help to increase the knowledge of health professionals about telemedicine.]

Long Covid is a complex condition characterised by symptoms that persist for weeks and months after the Covid infection, accompanied by cognitive im­pairment that negatively affects daily life. Understanding this complex condition is important for the development of diagnostic and therapeutic strategies. This article aims to provide a comprehensive overview of cognitive impairment in long-COVID.

To evaluate the long-term effects of the COVID-19 pandemic on seizure frequency and levels of mental distress in individuals with epilepsy and identify potential risk factors associated with increased seizure frequency. This is a cross-sectional study conducted in Türkiye in May 2021 by phone. Information on epilepsy syndromes, antiseizure medications, average seizure frequency, and drug resistance was obtained from medical records.

[A significant number of studies addresses the benefits of high-flow nasal oxygen therapy (HFNO) in respiratory failure caused by Covid-19. However, the number among them about its use outside the intensive care unit is much less. Our study aims to evaluate the HFNO treatment data of patients with respiratory failure caused by Covid-19 in non-intensive care settings, and to compare them with three international studies and one local study with re­sembling subject.

To this retrospective cohort study, we selected patients with respiratory failure (n = 47) caused by Covid-19 pneumonia who were treated at the wards of the Sub-intensive Infectious Diseases De­part­ment, at Tolna County Balassa János Hos­pital, between March 16, and May 31, 2021. Exclusion criteria of starting HFNO the­rapy were low GCS (<13), multiple or­gan failure requiring intensive therapy, and hypercapnia (paCO2 > 50 mm Hg). With the patients’ general demographic data, we also evaluated treatment outcomes and mor­tality. We compared the duration of treatment and the average number of days of hospital stay with the number of care days among other patients not treated with HFNO, during the span of the study and the previous wave of the pandemic.

The patients’ mean age was 66 years (median: 67). The average duration of HFNO treatment was 6.829 days, which means a sum of 321 treatment days for 47 patients. 45% of the patients could be discharged home, 25% had to be transferred to the intensive care unit because they need­ed invasive ventilation, which was determined by a modified version of the national early warning score (NEWS) point system. Mortality during treatment was 30% and those of patients transferred to the intensive care unit mounted to 83%.

Compared with other three international studies and one local study, further based on our own experience, HFNO has proven to be effective in the treatment of patients with respiratory insufficiency not associated with hypercapnia caused by severe Covid-19. Based on patient feedback and nursing documentation, it increased the patient comfort compared with conventional oxygen therapy devices. Compared with data collected in the previous pandemic wave, the HFNO therapy reduced the average number of hospital treatment days and reduced the burden of the intensive care unit too.]